|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,690.00 JPY | -1.18% |
|
-8.36% | +10.95% |
| 20/02 | Japan Panel Clears First iPS Cell Therapies for Conditional Sale | MT |
| 19/02 | Japanese government panel endorses Sumitomo Pharma's iPS-derived treatment for Parkinson's | RE |
| Capitalization | 5.52TCr 35Cr 30Cr 27Cr 26Cr 48Cr 3.2TCr 49Cr 326.32Cr 129.32Cr 1.53TCr 129.8Cr 127.06Cr | P/E ratio 2024 |
-43x | P/E ratio 2025 | -103x |
|---|---|---|---|---|---|
| Enterprise value | 5.04TCr 32Cr 28Cr 25Cr 24Cr 43Cr 2.92TCr 45Cr 297.99Cr 118.09Cr 1.4TCr 118.53Cr 116.03Cr | EV / Sales 2024 |
1,024x | EV / Sales 2025 | 356x |
| Free-Float |
66.29% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -1.18% | ||
| 1 week | -8.36% | ||
| Current month | -17.20% | ||
| 1 month | -20.92% | ||
| 3 months | +9.14% | ||
| 6 months | -10.68% | ||
| Current year | +10.95% |
| 1 week | 6,550 |  | 7,290 |
| 1 month | 6,480 | | 12,400 |
| Current year | 6,030 | | 12,400 |
| 1 year | 5,580 | | 12,400 |
| 3 years | 1,287 | | 12,400 |
| 5 years | 1,287 | | 12,400 |
| 10 years | 1,287 | | 12,400 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 01/06/2020 | |
Yoshiki Sawa
CTO | Chief Tech/Sci/R&D Officer | 70 | 01/08/2021 |
Kazuhiko Sakai
SAM | Sales & Marketing | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 01/06/2024 | |
| Director/Board Member | 67 | 01/08/2020 | |
Tadashi Samejima
BRD | Director/Board Member | 66 | 01/06/2022 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.18% | -8.36% | -5.11% | - | 35Cr | |
| -0.11% | -2.50% | +8.16% | -0.16% | 7.66TCr | |
| -1.19% | -3.22% | +37.90% | +211.14% | 5.54TCr | |
| -2.03% | +59.20% | +59.20% | +59.20% | 5.05TCr | |
| -0.01% | -3.73% | -43.67% | -50.70% | 4.81TCr | |
| -1.81% | -3.47% | +29.50% | -29.24% | 2.71TCr | |
| -1.55% | -2.36% | +50.13% | -61.99% | 2.11TCr | |
| +0.55% | -4.92% | +36.63% | +28.51% | 1.83TCr | |
| -1.10% | +3.06% | +107.84% | +108.11% | 1.81TCr | |
| -1.69% | -2.20% | +33.05% | +55.66% | 1.4TCr | |
| Average | -1.21% | -1.89% | +31.36% | +35.61% | 3.3TCr | |
| Weighted average by Cap. | -1.30% | -1.61% | +25.96% | +40.70% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 2.3Cr 1L 1L 1L 1L 2L 1.33Cr 2L 13.6L 5L 63.68L 5L 5L | 18Cr 10.96L 10L 9L 8L 15.07L 10Cr 15.66L 1.03Cr 40.99L 4.85Cr 41.15L 40.28L |
| Net income | -63Cr -39.6L -34.61L -31.27L -29.91L -54.41L -37Cr -56.56L -3.74Cr -1.48Cr -17Cr -1.49Cr -1.45Cr | -64Cr -40.35L -35.27L -31.86L -30.48L -55.44L -37Cr -57.63L -3.81Cr -1.51Cr -18Cr -1.51Cr -1.48Cr |
| Net Debt | -558.2Cr -3.5Cr -3.06Cr -2.76Cr -2.64Cr -4.81Cr -323.49Cr -5Cr -33Cr -13Cr -154.55Cr -13Cr -13Cr | -479.3Cr -3Cr -2.62Cr -2.37Cr -2.27Cr -4.13Cr -277.76Cr -4.29Cr -28Cr -11Cr -132.7Cr -11Cr -11Cr |
Employees
56
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/26/13 | 6,690.00 ¥ | -1.18% | 1,79,000 |
| 12/26/12 | 6,770.00 ¥ | -1.17% | 1,71,700 |
| 11/26/11 | 6,850.00 ¥ | -2.70% | 2,16,600 |
| 10/26/10 | 7,040.00 ¥ | -0.71% | 2,84,200 |
| 09/26/09 | 7,090.00 ¥ | -1.53% | 3,98,800 |
Annual profits - Rate of surprise
- Stock Market
- Equities
- 4894 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition